Business Development Deal Architecture
  • Search OnBioBD:

  • OnBioBD OldSkool NEWS:

    - OnBioVC 4Q11 Trend Analysis, now available
    - OnBioVC 1Q12 White Paper, now available
    - OnBioVC 1Q12 Trend Analysis, coming soon

  • FDA Registered Contract Manufacturer

Achaogen (San Francisco, CA) a clinical-stage a biopharmaceutical company focused on the discovery and development of broad-spectrum antibiotics to treat life-threatening, multi-drug resistant bacterial infections, closed a $56M Series C financing. Participants include Frazier Healthcare Ventures, Alta Partners, 5 AM Ventures, ARCH Venture Partners, Domain Associates, Venrock Associates, Versant Ventures and Wellcome Trust.

Bind Biosciences (Cambridge, MA) a preclinical-stage biopharmaceutical company focused on differential medicinal nanoengineered delivery of targeted therapeutics and controlled drug exposure to diseased tissue for various cancers, closed an $11M Series C financing. Participants have included DHK Investments, ARCH Venture Partners, Flagship Ventures, NanoDimension and Polaris Venture Partners.

Receptos (San Diego, CA) a preclinical stage biopharmaceutical company focused on structural biolog GPCR approaches targeting autoimmune disease, closed a $25M Series A financing. Participants include ARCH Venture Partners, Flagship Ventures, Lilly Ventures and Venrock. Note: 2009 Year-in-Review Trend Analysis Coming 15 Feb

Pulmatrix (Lexington, MA) a clinical-stage biotechnology company focused on the discovery and development of therapies for the treatment and prevention of infectious (COPD, asthma, and cystic fibrosis) and progressive respiratory (influenza, ventilator acquired pneumonia and respiratory syncytial virus (RSV)) diseases, closed a $30.2M Series B financing. Participants include Arch Venture Partners, Novartis Ventures Funds,Polaris Venture […]

Fate Therapeutics (La Jolla, CA) a pre-clinical biopharma company focused on developing small molecule and biologic drug candidates to modulate stem cell pathways to stimulate tissue regeneration and blocking cancer growth, closed a $30M Series B financing. Participants include OVP Venture Partners, ARCH Venture Partners, Polaris Venture Partners and Venrock. Note: 2009 Year-in-Review Trend Analysis […]

« Previous Page  Next Entries »

to top of page...